Supply of Alzheimer's patients in medical specialty retail
SKU:
$2,490.00
$2,490.00
per item
Description
In Germany, more than 500,000 people are suffering from dementia, while 2/3 of the patients suffer from Alzheimer's disease. The likelihood of developing dementia increases sharply from the age of 65. The process of dementia is unstoppable and needs to participate throughout the course of the disease of a continuous and complexity-increasing supply of medical supplies to the retailers, pharmacies and homecare providers.
The aim of the Qnidos Deutsche Health Intelligence study "To provide care for Alzheimer's patients in medical specialty retailers" is to give executives and decision-makers in the field of rehabilitation aids a comprehensive overview of the patient group of Alzheimer's sufferers in Germany. The focus of the market investigation is on the detailed presentation of the prevalence rates, the dissemination of the different forms of dementia and the development of patient numbers in recent years.
In addition to the information presented here and a detailed market outlook, the report answers the following questions concerning the German Alzheimer's market:
What are the risk factors and treatment options?
What type of follow-up and sequelae can occur?
What tools are needed at what stage of the disease?
What resources are refunded and which are not?
Who are the stakeholders in Alzheimer's care?
The aim of the Qnidos Deutsche Health Intelligence study "To provide care for Alzheimer's patients in medical specialty retailers" is to give executives and decision-makers in the field of rehabilitation aids a comprehensive overview of the patient group of Alzheimer's sufferers in Germany. The focus of the market investigation is on the detailed presentation of the prevalence rates, the dissemination of the different forms of dementia and the development of patient numbers in recent years.
In addition to the information presented here and a detailed market outlook, the report answers the following questions concerning the German Alzheimer's market:
What are the risk factors and treatment options?
What type of follow-up and sequelae can occur?
What tools are needed at what stage of the disease?
What resources are refunded and which are not?
Who are the stakeholders in Alzheimer's care?
